References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...

Geriatric Use: Of the 1287 patients with HER2-positive or HER2-low breast cancer treated with ENHERTU 5.4 mg/kg, 22% were ≥65 years and 3.8% were ≥75 years.

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

Geriatric Use: Of the 1741 patients with HER2-positive, HER2-low, or HER2-ultralow breast cancer treated with ENHERTU 5.4 mg/kg, 24% were ≥65 years and 4.9% were ≥75 years.

According to the press release from Daiichi Sankyo, it is estimated that approximately 60-65% of HR-positive, HER2-negative breast cancers are HER2-low. Up to 25% may also be HER2-ultralow. In 2022, ...

The Food and Drug Administration (FDA) approved AstraZeneca’s Enhertu to treat HER2-low breast cancer. Enhertu is the first targeted treatment for this subtype of breast cancer. Following the ...

Treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) doubled progression-free survival (time during and after treatment when a patient lives without disease progression) in patients with HER2-low, ...

HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body ... Before you receive ENHERTU, tell your healthcare provider about all of your medical ...

After spearheading the new HER2-low category in breast cancer treatment, Enhertu has shown it could be useful against tumors with even lower expression of the HER2 protein. AZ, Daiichi tout ...

Enhertu is also approved for the treatment of unresectable or metastatic HER2-positive breast cancer in patients who have received 2 or more prior anti-HER2-based regimens in the metastatic setting.

TOKYO & BASKING RIDGE, N.J., January 27, 2025--ENHERTU Approved in the U.S. as First HER2 Directed Therapy for HER2 Low or HER2 Ultralow mBC Following Disease Progression After Endocrine Therapy ...

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’ s ENHERTU is the first HER2 directed therapy to demonstrate a survival benefit in this population Application being ...